IDO inhibitors
Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.
1. A solid pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent, or carrier and a compound selected from the group consisting of:
O-((4,4′-dichlorobiphenyl-2-yl)methyl)hydroxylamine;
O-(5-chloro-2-(thiophen-3-yl)benzyl)hydroxylamine;
O-((4′-chlorobiphenyl-2-yl)methyl)hydroxylamine;
O-(5-chloro-2-(thiophen-2-yl)benzyl)hydroxylamine;
methyl 4-(aminooxy)-4-phenylbutanoate;
O-((4′-chlorobiphenyl-3-yl)methyl)hydroxylamine;
O-((3′,4,4′-trichlorobiphenyl-2-yl)methyl)hydroxylamine;
O-(5-chloro-2-(pyrimidin-5-yl)benzyl)hydroxylamine;
O-(5-chloro-2-(1H-indol-5-yl)benzyl)hydroxylamine;
(S)-2-(aminooxy)-N-methyl-2-phenylacetamide;
methyl 2-(aminooxy)-2-phenylacetate;
O-(1,3-diphenylpropyl)hydroxylamine;
3-(aminooxymethyl)-N-phenylaniline;
O-((4′,5-dichlorobiphenyl-3-yl)methyl)hydroxylamine;
2-(aminooxymethyl)-N-benzylaniline;
O-(3-cyclohexyl-1-phenylpropyl)hydroxylamine;
2-(aminooxymethyl)-N-phenylaniline;
O-(cyclohexyl(phenyl)methyl)hydroxylamine;
2-(aminooxy)-N-methyl-2-phenylacetamide;
O-(1,2-diphenylethyl)hydroxylamine;
O-(1,2,3,4-tetrahydronaphthalen-1-yl)hydroxylamine;
3-(aminooxymethyl)-N-benzylaniline;
O-(2-(pyridin-4-yl)benzyl)hydroxylamine;
O-(3-(pyridin-4-yl)benzyl)hydroxylamine;
O-(2-cyclohexyl-1-phenylethyl)hydroxylamine;
4-(aminooxy)-N-methyl-4-phenylbutanamide;
2-(aminooxy)-2-phenylethanamine;
3-(aminooxy)-3-phenylpropan-1-amine;
O-(2-morpholino-1-phenylethyl)hydroxylamine;
3-(aminooxymethyl)-N-benzylaniline;
2-(aminooxy)-N-methyl-2-phenylethanamine;
4-(aminooxy)-N-cyclohexyl-4-phenylbutanamide;
tert-butyl 2-(aminooxy)-2-phenylethylcarbamate;
(R)-2-(aminooxy)-N-methyl-2-phenylacetamide;
3-(aminooxy)-N-methyl-3-phenylpropan-1-amine;
N-(2-(aminooxy)-2-phenylethyl)acetamide;
O-(3-morpholino-1-phenylpropyl)hydroxylamine; and
(S)-3-(aminooxy)-3-phenylpropan-1-ol;
or a pharmaceutically acceptable salt thereof.